VYGR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Voyager Therapeutics Inc (VYGR) is not a strong buy at the moment for a beginner investor with a long-term focus. The stock lacks clear positive catalysts, has weak financial performance, and insider selling activity is high. While the technical indicators are neutral, and options data suggests low put-call ratios, these are not sufficient to justify a buy decision given the overall context.
The MACD histogram is positive but contracting, RSI is neutral at 46.796, and moving averages are converging. Key support and resistance levels are close to the current price, with the pivot at 3.935, indicating no strong trend. Overall, the technical indicators suggest a neutral stance.
No significant positive catalysts. The AI Stock Picker and SwingMax signals are absent, and there are no recent positive developments in the news or trading trends.
Insider selling has increased by 591.56% over the last month, which is a strong negative signal. Additionally, the company's financial performance in Q3 2025 showed a significant revenue drop of -45.73% YoY, and the stock trend analysis predicts a -1.46% decline over the next month. The strained relationship between UniQure and the FDA, as highlighted in the news, could also indirectly impact the biotech sector sentiment.
In Q3 2025, revenue dropped by -45.73% YoY to $13.37M. Net income improved to -$27.89M, up 208.40% YoY, but remains negative. EPS increased to -0.47, up 193.75% YoY, while gross margin remained flat at 100%. Overall, the financials show improvement in losses but a significant decline in revenue, which is concerning.
Morgan Stanley recently raised the price target from $25 to $39 but maintained an Equal Weight rating. This indicates cautious optimism but not a strong buy recommendation.
